Cardiovascular outcomes and subclinical atherosclerosis in metabolic-associated steatotic liver disease: long-term follow-up from a specialized outpatient cohort

Key Points

• Cardiovascular events were lower than expected in metabolic-associated steatotic liver disease patients, signaling effective prevention.
• Only 25% of patients experienced major cardiovascular events during the long-term follow-up, indicating favorable outcomes.
• Observational analysis across a specialized outpatient cohort revealed persistent subclinical atherosclerosis despite improved cardiovascular events.
• New insights into metabolic-associated steatotic liver disease underline the need for ongoing monitoring and management of atherosclerotic risks.